The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
OBJECTIVE
Dihydropyrimidine dehydrogenase (DPD) deficiency is critical in the predisposition to 5-fluorouracil dose-related toxicity. We recently characterized the phenotypic [2-(13)C]uracil breath test (UraBT) with 96% specificity and 100% sensitivity for identification of DPD deficiency. In the present study, we characterize the relationships among UraBT-associated breath (13)CO(2) metabolite formation, plasma [2-(13)C]dihydrouracil formation, [2-(13)C]uracil clearance, and DPD activity.


METHODS
An aqueous solution of [2-(13)C]uracil (6 mg/kg) was orally administered to 23 healthy volunteers and 8 cancer patients. Subsequently, breath (13)CO(2) concentrations and plasma [2-(13)C]dihydrouracil and [2-(13)C]uracil concentrations were determined over 180 minutes using IR spectroscopy and liquid chromatography-tandem mass spectrometry, respectively. Pharmacokinetic variables were determined using noncompartmental methods. Peripheral blood mononuclear cell (PBMC) DPD activity was measured using the DPD radioassay.


RESULTS
The UraBT identified 19 subjects with normal activity, 11 subjects with partial DPD deficiency, and 1 subject with profound DPD deficiency with PBMC DPD activity within the corresponding previously established ranges. UraBT breath (13)CO(2) DOB(50) significantly correlated with PBMC DPD activity (r(p) = 0.78), plasma [2-(13)C]uracil area under the curve (r(p) = -0.73), [2-(13)C]dihydrouracil appearance rate (r(p) = 0.76), and proportion of [2-(13)C]uracil metabolized to [2-(13)C]dihydrouracil (r(p) = 0.77; all Ps < 0.05).


CONCLUSIONS
UraBT breath (13)CO(2) pharmacokinetics parallel plasma [2-(13)C]uracil and [2-(13)C]dihydrouracil pharmacokinetics and are an accurate measure of interindividual variation in DPD activity. These pharmacokinetic data further support the future use of the UraBT as a screening test to identify DPD deficiency before 5-fluorouracil-based therapy.
Mattison
Lori K
LK
Division of Clinical Pharmacology and Toxicology, Comprehensive Cancer Center, University of Alabama at Birmingham, 1824 6th Avenue South, Birmingham, AL 35294, USA.
Fourie
Jeanne
J
Hirao
Yukihiro
Y
Koga
Toshihisa
T
Desmond
Renee A
RA
King
Jennifer R
JR
Shimizu
Takefumi
T
Diasio
Robert B
RB
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001944:Breath Tests; D002245:Carbon Dioxide / Q000378:metabolism*; D002247:Carbon Isotopes; D002851:Chromatography, High Pressure Liquid; D003955:Diagnostic Tests, Routine; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000378:metabolism; D010641:Phenotype; D012680:Sensitivity and Specificity; D013055:Spectrophotometry, Infrared; D014498:Uracil / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*
D002247:Carbon Isotopes; C007419:dihydrouracil; D002245:Carbon Dioxide; D014498:Uracil; D042943:Dihydrouracil Dehydrogenase (NADP)